NRAS and neoplasm: In some instances (12/254, 5% for THCA and 16/186, 9% for SKCM), the tumors displayed additional mutations in the RAS pathway (NRAS, NF1, and CKIT) and were discarded from the analyses presented in Fig. 1A. In both these tumor types, NAMPT expression was significantly higher in patients harboring BRAF mutations [SKCM: 170 BRAF-MUT vs. 63 BRAF-WT, P = 0.0006, and THCA: 242 BRAF-MUT vs. 127 BRAF-WT, P = 10–15 (Fig. 1B)].